Hemant Surgical Industries approved its Directors' Report and Management Discussion and Analysis for the financial year ended March 31, 2026. The board also scheduled the company's 37th Annual General Meeting.

The meeting of the Board of Directors was held on Saturday, August 29, 2026. It commenced at 11:50 am and concluded at 12:10 pm. The approvals were made in compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Annual General Meeting Details

The company will hold its 37th AGM on Tuesday, September 29, 2026. The meeting is scheduled to begin at 12:30 pm. Shareholders can attend through Video Conferencing or Other Audio-Visual Means.

The Managing Director, Hanskumar Shamji Shah, signed the disclosure filed with BSE Limited.

Hemant Surgical Industries Limited has revised its disclosure regarding the Semi Knocked Down (SKD) Manufacturing Agreement with Sonomed Escalon, USA, to provide better clarity to investors. The agreement, initially disclosed on March 31, 2026, outlines the framework for manufacturing specific ophthalmic devices in India. The modifications were made at the request of Sonomed Escalon to enhance understanding of the arrangement.

The primary objective of the agreement is to undertake SKD manufacturing in India of two designated models of A-scan and pachymetry ophthalmic ultrasound devices. These products will be distributed exclusively within the Indian market. The scope of work for both parties has been defined according to SKD protocols and further localisation requirements.

Sonomed Escalon has agreed to supply components in SKD form at a preferential "Transfer Price." The pricing structure established under the agreement is exclusive of taxes, duties, customs, statutory levies, and shipping costs, unless otherwise agreed upon by the parties involved.

The regulatory filing confirms that there is no shareholding by Hemant Surgical Industries in Sonomed Escalon. Furthermore, the transaction does not fall under related party transactions, nor does it involve any special rights such as the appointment of directors or restrictions on capital structure. The promoter of Hemant Surgical Industries was previously an authorised distributor of Sonomed Escalon.

The revised disclosure was submitted to BSE Limited on June 09, 2026, in compliance with SEBI Circular SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The filing was signed by Hanskumar Shamji Shah, Managing Director of Hemant Surgical Industries Limited.

Agreement Details